Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 16, 2015 08:00 ET | Source: Bioblast Pharma Ltd.

BioBlast Pharma Announces Appointment of Tom Dubin, Former Alexion SVP & Chief Legal Officer, to the Board of Directors

NEW HAVEN, Conn., Sept. 16, 2015 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd., (Nasdaq:ORPN), a clinical-stage biotechnology company committed to developing meaningful therapies for patients with rare and...
September 14, 2015 08:00 ET | Source: Bioblast Pharma Ltd.

BioBlast Granted Patent From USPTO for Cabaletta for the Treatment of Spinocerebellar Ataxia (SCA)

TEL AVIV, Israel, Sept. 14, 2015 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage orphan disease-focused biotechnology company, announced today that it was granted a patent...
September 10, 2015 08:00 ET | Source: Bioblast Pharma Ltd.

BioBlast Pharma Augments Leadership Team and Establishes U.S. Headquarters in New Haven, Connecticut

NEW HAVEN, Conn., Sept. 10, 2015 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd., (Nasdaq:ORPN), a clinical-stage biotechnology company committed to developing meaningful therapies for patients with rare and...
September 08, 2015 08:00 ET | Source: Bioblast Pharma Ltd.

BioBlast Pharma to Present at Rodman & Renshaw Conference on September 10

TEL AVIV, Israel, Sept. 8, 2015 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced today that Colin Foster, President and...
August 21, 2015 08:00 ET | Source: Bioblast Pharma Ltd.

BioBlast Pharma Reports Second Quarter Financial Results

TEL AVIV, Israel, Aug. 21, 2015 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the second...
June 29, 2015 08:00 ET | Source: Bioblast Pharma Ltd.

BioBlast Pharma Receives Orphan Drug Designation From the European Commission for Cabaletta for the Treatment of Spinocerebellar Ataxia (SCA)

TEL AVIV, Israel, June 29, 2015 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage orphan disease-focused biotechnology company, announced today that it has been granted Orphan...
June 25, 2015 08:00 ET | Source: Bioblast Pharma Ltd.

BioBlast Pharma Receives Orphan Drug Designation From the European Commission for Cabaletta for the Treatment of Oculopharyngeal Muscular Dystrophy

TEL AVIV, Israel, June 25, 2015 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage orphan disease-focused biotechnology company, announced today that it has been granted Orphan...
June 22, 2015 07:18 ET | Source: Bioblast Pharma Ltd.

BioBlast Announces Positive Preclinical Proof-Of-Concept Results of Its Novel Read-Through Platform in Spinal Muscular Atrophy (SMA)

TEL AVIV, Israel, June 22, 2015 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage orphan disease-focused biotechnology company, announced today positive preclinical in vitro...
June 18, 2015 08:00 ET | Source: Bioblast Pharma Ltd.

BioBlast Pharma to Present Preclinical Proofs of Concept in Spinal Muscular Atrophy and Friedreich's Ataxia at Two Leading Scientific Meetings in June

TEL AVIV, Israel, June 18, 2015 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage orphan disease-focused biotechnology company, announced today that it will present pre-clinical...
June 15, 2015 08:00 ET | Source: Bioblast Pharma Ltd.

BioBlast Announces the Start of a Phase 3 Study for Cabaletta in Oculopharyngeal Muscular Dystrophy (OPMD)

TEL AVIV, Israel, June 15, 2015 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage orphan disease-focused biotechnology company, announced today the start of a Phase 3 pivotal...